Busy. Please wait.
or

show password
Forgot Password?

Don't have an account?  Sign up 
or

Username is available taken
show password

why


Make sure to remember your password. If you forget it there is no way for StudyStack to send you a reset link. You would need to create a new account.
We do not share your email address with others. It is only used to allow you to reset your password. For details read our Privacy Policy and Terms of Service.


Already a StudyStack user? Log In

Reset Password
Enter the associated with your account, and we'll email you a link to reset your password.

Remove ads
Don't know
Know
remaining cards
Save
0:01
To flip the current card, click it or press the Spacebar key.  To move the current card to one of the three colored boxes, click on the box.  You may also press the UP ARROW key to move the card to the "Know" box, the DOWN ARROW key to move the card to the "Don't know" box, or the RIGHT ARROW key to move the card to the Remaining box.  You may also click on the card displayed in any of the three boxes to bring that card back to the center.

Pass complete!

"Know" box contains:
Time elapsed:
Retries:
restart all cards




share
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.

  Normal Size     Small Size show me how

NURS 572 Pharm 56a

Pharm Diabetes Mellitus Drug drill only

QuestionAnswer
regular insulin quick/short insulin
lispro quicker/shorter insulin
aspart quicker/shorter insulin
glulisine quicker/shorter insulin
NPH = neutral protamine hagedorn intermediate insulin that can be mixed with quicker shorter and quick short (regular)
detemir long acting insulin
glargine super long insulin
glipizide, safe in elderly, renal impaired sulfonylureas - secretagogue
glyburide sulfonylureas - secretagogue
glimepiride sulfonylureas - secretagogue
repaglinide meglitinide - secretagogue
nateglinide meglitinide - secretagogue
metformin biguadide whose primary MOA is to decrease glycogenolysis. secondary MOA to increase receptor sensitivity. ADR lactic acidosis
pioglitazone glitazone whose primary MOA is increased receptor sensitivity. secondary MOA is decreased glycogenolysis. ADR hepatotoxic
rosglitazone glitazone whose primary MOA is increased receptor sensitivity. secondary MOA is decreased glycogenolysis. ADR hepatotoxic
acarbose alpha-glucosidase inhibitor
miglitol alpha-glucosidase inhibitor
pramlinitide injectible amylin mimetic
exenatide BID injectible incretin memetic
liraglutide QD injectible incretin mimetic
sitagliptin oral QD DPP4 inhibitor that potentiates incretin
saxagliptin oral QD DPP4 inhibitor that potentiates incretin
linagliptin oral QD DPP4 inhibitor that potentiates incretin
Created by: lorrelaws